Mannatech Reports Steep Losses, Negative Equity, and Revenue Decline for 2025 Following Delayed 10-K Filing
MTEX is trading near its 52-week low of $4.665 (6.3% above the low) on light trading volume (0.2× avg).
Summary
Mannatech reported a significant net loss of $15.2 million for 2025, resulting in negative shareholders' equity, alongside an 8.3% decline in annual net sales and a shift to an operating loss.
Key Events · Earnings and Guidance · MTEX
-
Significant Net Loss Reported
The company reported a net loss of $15.2 million, or $8.00 per diluted share, for the full year 2025, a sharp decline from a net income of $2.5 million in 2024. The fourth quarter also saw a net loss of $11.3 million, or $5.94 per diluted share, compared to a net income of $2.3 million in Q4 2024.
-
Shareholders' Equity Turns Negative
Total shareholders' equity decreased from $8.6 million at the end of 2024 to a negative $5.2 million as of December 31, 2025, primarily due to the substantial net loss.
-
Revenue Decline Continues
Net sales for 2025 decreased by 8.3% to $108.0 million from $117.9 million in 2024. Fourth-quarter net sales also declined by 8.2% to $26.6 million.
-
Shift to Operating Loss
Mannatech recorded an operating loss of $0.4 million for the full year 2025, compared to an operating income of $1.4 million in 2024. The fourth quarter also saw an operating loss of $0.2 million.
Analysis · MTEX · Life Sciences
Mannatech's 2025 financial results, released via this 8-K and a concurrent 10-K filing, reveal a significant deterioration in financial health. The company reported a substantial net loss for both the fourth quarter and the full year, primarily driven by a large non-cash deferred income tax charge. Critically, the company's shareholders' equity has turned negative, indicating a precarious financial position for this micro-cap company. The ongoing decline in net sales and the shift from operating income to operating loss further underscore the operational challenges. This report follows a previously announced delay in filing the 10-K, which now clarifies the severity of the issues. Investors should be highly concerned about the company's ability to reverse these trends and maintain long-term viability given the negative equity and cash burn.
At the time of this filing, MTEX was trading at $4.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.4M. The 52-week trading range was $4.67 to $12.45. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.